Cleary Gottlieb represented AnPac Bio-Medical Science Co. Ltd. (AnPac Bio) in its $16 million initial public offering.
The deal priced on January 29, 2020, and closed on February 3, 2020. AnPac Bio’s American Depositary Shares, each representing one of its Class A ordinary shares, par value $0.01 per share, began trading on the Nasdaq Global Market on January 30, 2020.
AnPac Bio is a biotechnology company focusing on early cancer screening and detection. It has two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States. Its CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.